08.19.21
Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to address IgE-mediated food allergy, has initiated the buildout of a new state-of-the-art manufacturing facility to support future production of its lead product candidate, ADP101. ADP101 is a novel, investigational oral immunotherapy designed to address allergies to one or to multiple foods associated with 90% of severe reactions. The 53,000 square foot manufacturing and warehouse facility is located near the company’s contract manufacturing organization (CMO) in the greater Philadelphia area.
“One of the great strengths of Alladapt is our technical operations team, which has spent years addressing the specialized, novel challenges associated with producing pharmaceutical-grade single-and multi-allergen oral immunotherapeutic agents,” said Mike Holfinger, chief technical officer, Alladapt. “With our Harmony Study actively enrolling, it is exciting to build on our technical achievements by initiating scale-up beyond our Phase 1/2-enabling processes.”
Ashley Dombkowski, CEO, Alladapt, said, “Securing this facility reflects our confidence in this program and marks an important step toward achieving full-scale production capacity to support our Phase 3 program and potential future commercial launch. These investments reaffirm our commitment to transforming the food allergy treatment landscape by advancing therapeutic options to broadly address this chronic and potentially life-threatening disease.”
“One of the great strengths of Alladapt is our technical operations team, which has spent years addressing the specialized, novel challenges associated with producing pharmaceutical-grade single-and multi-allergen oral immunotherapeutic agents,” said Mike Holfinger, chief technical officer, Alladapt. “With our Harmony Study actively enrolling, it is exciting to build on our technical achievements by initiating scale-up beyond our Phase 1/2-enabling processes.”
Ashley Dombkowski, CEO, Alladapt, said, “Securing this facility reflects our confidence in this program and marks an important step toward achieving full-scale production capacity to support our Phase 3 program and potential future commercial launch. These investments reaffirm our commitment to transforming the food allergy treatment landscape by advancing therapeutic options to broadly address this chronic and potentially life-threatening disease.”
